olfactory receptor family 13 subfamily C member 9Genealiases: OR37L · OR9-13
Q-omics provides the consensus-scored OR13C9 profile across patient tissues and cancer cell-line models. OR13C9 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, OR13C9 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, OR13C9 RNA expression shows 12,080 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight STAD, KIRC, and COAD as cancer lineages where OR13C9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR13C9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR13C9 survival associations across molecular data types. OR13C9 RNA expression shows survival associations in the most cancer types (12), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR13C9 RNA expression–survival associations across cancer types. High OR13C9 expression shows unfavorable associations in STAD, ACC, LIHC, HNSC and BLCA, but favorable associations in UCS. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for OR13C9 RNA expression.
This table summarizes OR13C9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR13C9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR13C9 shows lower tumor expression in KIRC and THCA. The KIRC box plot shows higher OR13C9 RNA expression in normal versus tumor tissue (log2 FC = −0.011, t-test p = .001).
This table shows molecular features associated with OR13C9 in patient tissues and cancer cell lines. In patient samples, OR13C9 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR13C9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and CNS.
